Literature DB >> 22794678

Chapter 5: Allergic rhinitis.

Ashraf Uzzaman, Rachel Story.   

Abstract

Rhinitis is a symptomatic inflammatory disorder of the nose with different causes such as allergic, nonallergic, infectious, hormonal, drug induced, and occupational and from conditions such as sarcoidosis and necrotizing antineutrophil cytoplasmic antibodies positive (Wegener's) granulomatosis. Allergic rhinitis affects up to 40% of the population and results in nasal (ocular, soft palate, and inner ear) itching, congestion, sneezing, and clear rhinorrhea. Allergic rhinitis causes extranasal untoward effects including decreased quality of life, decreased sleep quality, obstructive sleep apnea, absenteeism from work and school, and impaired performance at work and school termed "presenteeism." The nasal mucosa is extremely vascular and changes in blood supply can lead to obstruction. Parasympathetic stimulation promotes an increase in nasal cavity resistance and nasal gland secretion. Sympathetic stimulation leads to vasoconstriction and consequent decrease in nasal cavity resistance. The nasal mucosa also contains noradrenergic noncholinergic system, but the contribution to clinical symptoms of neuropeptides such as substance P remains unclear. Management of allergic rhinitis combines allergen avoidance measures with pharmacotherapy, allergen immunotherapy, and education. Medications used for the treatment of allergic rhinitis can be administered intranasally or orally and include oral and intranasal H(1)-receptor antagonists (antihistamines), intranasal and systemic corticosteroids, intranasal anticholinergic agents, and leukotriene receptor antagonists. For intermittent mild allergic rhinitis, an oral or intranasal antihistamine is recommended. In individuals with persistent moderate/severe allergic rhinitis, an intranasal corticosteroid is preferred. When used in combination, an intranasal H(1)-receptor antagonist and a nasal steroid provide greater symptomatic relief than monotherapy. Allergen immunotherapy is the only disease-modifying intervention available.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22794678     DOI: 10.2500/aap.2012.33.3535

Source DB:  PubMed          Journal:  Allergy Asthma Proc        ISSN: 1088-5412            Impact factor:   2.587


  6 in total

1.  Allergic Rhinitis in Children: A Randomized Clinical Trial Targeted at Symptoms.

Authors:  Nicola Mansi; Gabriele D'Agostino; Antonella Silvia Scirè; Giada Morpurgo; Dario Gregori; Achal Gulati; Valerio Damiani
Journal:  Indian J Otolaryngol Head Neck Surg       Date:  2014-02-11

2.  Association between promoter polymorphisms of interleukin-4 gene and allergic rhinitis risk: a meta-analysis.

Authors:  Zhi-Peng Li; Li-Li Yin; Hui Wang; Li-Si Liu
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2014-06-18

3.  Effect of nasal sprays on an in vitro survival and morphology of nasoseptal cartilage.

Authors:  Katharina Stoelzel; Benjamin Kohl; Mariann Hoyer; Carola Meier; Agnieszka J Szczepek; Heidi Olze; Gundula Schulze-Tanzil
Journal:  Eur Arch Otorhinolaryngol       Date:  2014-07-04       Impact factor: 2.503

4.  Sneezing reflex is mediated by a peptidergic pathway from nose to brainstem.

Authors:  Fengxian Li; Haowu Jiang; Xiaolei Shen; Weishan Yang; Changxiong Guo; Zhiyao Wang; Maolei Xiao; Lian Cui; Wenqin Luo; Brian S Kim; Zhoufeng Chen; Andrew J W Huang; Qin Liu
Journal:  Cell       Date:  2021-06-15       Impact factor: 66.850

Review 5.  Non-infectious Inflammatory Lesions of the Sinonasal Tract.

Authors:  Timothy R Helliwell
Journal:  Head Neck Pathol       Date:  2016-02-01

6.  The Role of the Level of Interleukin-33 in the Therapeutic Outcomes of Immunotherapy in Patients with Allergic Rhinitis.

Authors:  Wail Fayez Nasr; Samir Sorour Sorour; Atef Taha El Bahrawy; Ghada Samir Boghdadi; Alia A El Shahaway
Journal:  Int Arch Otorhinolaryngol       Date:  2017-08-28
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.